Saturday 17 October 2026
Export MDT’s income statement to Excel — free account
Medtronic PLC
MDT Healthcare Medical Devices
Medtronic PLC’s revenue for fiscal 2026 (year ended April 2026) was $36.4 billion, up 8.43% from fiscal 2025. In the quarter to July 2026, revenue grew 13.7%, EPS grew 42.0%, free cash flow grew 120.9% and total debt fell 1.59%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for three, operating cash flow growth for three.
94.75
0.70
−0.73%
Follow MDT
| Older periods | Oct '25 | Jan '26 | Apr '26 | Jul '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
24.45 | 28.61 | 21.65 | 20.93 |
P/S ratio |
3.35 | 3.71 | 2.85 | 2.91 | |
P/FCF ratio |
22.34 | 24.35 | 19.13 | 17.82 | |
P/Operating CF |
125.71 | 48.01 | 40.34 | 60.95 | |
P/B ratio |
2.38 | 2.68 | 2.07 | 2.15 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.94 | 4.27 | 3.37 | 3.43 | |
EV/EBITDA |
14.85 | 16.62 | 13.00 | 13.23 | |
EV/Operating CF |
19.27 | 20.79 | 16.72 | 16.01 | |
EV/FCF |
26.33 | 27.99 | 22.58 | 20.97 | |
Quick Ratio |
1.48 | 1.55 | 1.36 | 1.29 | |
Current Ratio |
2.42 | 2.54 | 2.13 | 2.07 | |
Net Debt/EBITDA |
8.55 | 8.90 | 7.24 | 7.76 | |
Debt/Assets |
31.86% | 30.68% | 30.06% | 30.17% | |
Debt/Equity |
0.60 | 0.57 | 0.56 | 0.55 | |
Asset Turnover |
0.38 | 0.39 | 0.39 | 0.41 | |
Operating CF/Net income |
0.67 | 2.40 | 2.07 | 1.22 | |
Capex/Depreciation |
(0.63) | (0.59) | (0.68) | (0.69) | |
Interest Coverage |
9.31 | 8.08 | 10.58 | 9.48 | |
Research and Development Expense of Revenue |
8.41% | 8.01% | 6.84% | 7.90% | |
Selling, General and Administrative Expense of Revenue |
33.09% | 32.78% | 31.17% | 32.78% | |
Intangible Assets out of Total Assets |
0.58 | 0.57 | 0.57 | 0.57 | |
Share Based Compensation of Revenue |
2.03% | 1.04% | 0.97% | 1.28% | |
Graham Net Nets |
(0.16) | (0.14) | (0.18) | (0.17) | |
Graham Number |
56.40 | 55.66 | 57.33 | 60.39 | |
Earnings Yield |
4.09% | 3.50% | 4.62% | 4.78% | |
Free Cash Flow Yield |
4.48% | 4.11% | 5.23% | 5.61% | |
Revenue per Share |
6.99 | 7.03 | 7.65 | 7.62 | |
Operating CF per Share |
0.72 | 2.14 | 2.01 | 1.40 | |
Capex per Share |
(0.37) | (0.35) | (0.38) | (0.39) | |
Free Cash Flow per Share |
0.36 | 1.79 | 1.63 | 1.01 | |
Cash per Share |
6.50 | 6.54 | 7.19 | 6.89 | |
Shareholders Equity per Share |
38.11 | 38.36 | 39.06 | 39.73 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
38.11 | 38.36 | 39.06 | 39.73 | |
Free Cash Flow |
457.00 | 2,300.00 | 2,085.00 | 1,290.00 | |
Working Capital |
14,061.00 | 14,576.00 | 13,129.00 | 12,591.00 | |
Capital Expenditures |
(468.00) | (444.00) | (488.00) | (503.00) | |
Net Current Asset Value |
(18,493.00) | (18,218.00) | (18,169.00) | (18,066.00) | |
EV/EBIT |
22.06 | 25.11 | 18.95 | 18.95 | |
Capex to Sales |
0.05 | 0.05 | 0.05 | 0.05 | |
Price to Operating Income |
18.72 | 21.85 | 16.05 | 16.10 | |
| Other line items | |||||
Average Receivables |
6,324.50 | 6,237.00 | 6,579.00 | 6,310.00 | |
Average Payables |
2,478.50 | 2,427.50 | 2,546.50 | 2,625.00 | |
Average Inventory |
5,817.50 | 5,959.50 | 5,713.50 | 6,050.50 | |
Average Assets |
90,694.00 | 90,729.00 | 92,354.00 | 92,139.00 | |
Average Common Equity |
48,785.50 | 49,406.00 | 49,164.50 | 49,492.00 |
Columns are period end dates